Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 286

1.

Ethyl Pyruvate Improves Pulmonary Function in Mice with Bleomycin-induced Lung Injury as Monitored with Hyperpolarized 129Xe MR Imaging.

Hodono S, Shimokawa A, Stewart NJ, Yamauchi Y, Nishimori R, Yamane M, Imai H, Fujiwara H, Kimura A.

Magn Reson Med Sci. 2018 Mar 9. doi: 10.2463/mrms.mp.2017-0163. [Epub ahead of print]

2.

The safety of gliptins : updated data in 2018.

Scheen AJ.

Expert Opin Drug Saf. 2018 Apr;17(4):387-405. doi: 10.1080/14740338.2018.1444027. Epub 2018 Mar 3. Review.

PMID:
29468916
3.

Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis.

Amano Y, Tsuchiya S, Imai M, Tohyama K, Matsukawa J, Isono O, Yasuno H, Enya K, Koumura E, Nagabukuro H.

Biochem Biophys Res Commun. 2018 Feb 26;497(1):207-213. doi: 10.1016/j.bbrc.2018.02.055. Epub 2018 Feb 9.

PMID:
29428719
4.

Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.

Takayanagi R, Uchida T, Kimura K, Yamada Y.

Biol Pharm Bull. 2018;41(2):153-157. doi: 10.1248/bpb.b17-00237.

5.

Evaluation of the Effect of Alogliptin on Tissue Characteristics of the Carotid Wall: Subanalysis of the SPEAD-A Trial.

Irie Y, Katakami N, Mita T, Takahara M, Matsuoka TA, Gosho M, Watada H, Shimomura I; Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Collaborators.

Diabetes Ther. 2018 Feb;9(1):317-329. doi: 10.1007/s13300-018-0367-7. Epub 2018 Jan 12.

6.

The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial.

Kanozawa K, Noguchi Y, Sugahara S, Nakamura S, Yamamoto H, Kaneko K, Kono R, Sato S, Ogawa T, Hasegawa H, Katayama S.

Clin Exp Nephrol. 2017 Dec 23. doi: 10.1007/s10157-017-1521-7. [Epub ahead of print]

PMID:
29275488
7.

Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis.

Guo WQ, Li L, Su Q, Dai WR, Ye ZL.

Value Health. 2017 Dec;20(10):1427-1430. doi: 10.1016/j.jval.2017.04.010. Epub 2017 May 29.

PMID:
29241903
8.

Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials.

Coppolino G, Leporini C, Rivoli L, Ursini F, di Paola ED, Cernaro V, Arturi F, Bolignano D, Russo E, De Sarro G, Andreucci M.

Pharmacol Res. 2018 Mar;129:274-294. doi: 10.1016/j.phrs.2017.12.001. Epub 2017 Dec 6. Review.

PMID:
29223646
9.

The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.

Yang J, Huang C, Wu S, Xu Y, Cai T, Chai S, Yang Z, Sun F, Zhan S.

PLoS One. 2017 Dec 5;12(12):e0187537. doi: 10.1371/journal.pone.0187537. eCollection 2017.

10.

Zinc/alogliptin combination attenuates testicular toxicity induced by doxorubicin in rats: Role of oxidative stress, apoptosis and TGF-β1/NF-κB signaling.

Kabel AM.

Biomed Pharmacother. 2018 Jan;97:439-449. doi: 10.1016/j.biopha.2017.10.144. Epub 2017 Nov 6.

PMID:
29091894
11.

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.

Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ.

Circulation. 2017 Aug 29;136(9):849-870. doi: 10.1161/CIRCULATIONAHA.117.028136. Review.

PMID:
28847797
12.

Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis.

Wu S, Chai S, Yang J, Cai T, Xu Y, Yang Z, Zhang Y, Ji L, Sun F, Zhan S.

Clin Ther. 2017 Sep;39(9):1780-1789.e33. doi: 10.1016/j.clinthera.2017.07.036. Epub 2017 Aug 18. Review.

PMID:
28827024
13.

Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients.

Ayers D, Kanters S, Goldgrub R, Hughes M, Kato R, Kragh N.

Curr Med Res Opin. 2017 Sep;33(9):1653-1661. doi: 10.1080/03007995.2017.1345730. Epub 2017 Jul 19. Review.

PMID:
28635331
14.

Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus.

Shimoda M, Miyoshi-Takai M, Irie S, Tanabe A, Obata A, Okauchi S, Hirukawa H, Kimura T, Kohara K, Kamei S, Mune T, Kaku K, Kaneto H.

J Diabetes Res. 2017;2017:5856475. doi: 10.1155/2017/5856475. Epub 2017 May 25.

16.

[Cardiovascular Effects of Antidiabetic Therapies].

Laubner K, Seufert J.

Dtsch Med Wochenschr. 2017 May;142(10):737-745. doi: 10.1055/s-0043-100564. Epub 2017 May 17. German.

PMID:
28514822
17.

Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists.

Scheen AJ.

Diabetes Res Clin Pract. 2017 May;127:224-237. doi: 10.1016/j.diabres.2017.03.009. Epub 2017 Mar 25. Review.

PMID:
28402902
18.

SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.

Lingvay I.

Endocr Pract. 2017 Jul;23(7):831-840. doi: 10.4158/EP161725.RA. Epub 2017 Mar 23. Review.

PMID:
28332871
19.

The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.

Secrest MH, Udell JA, Filion KB.

Trends Cardiovasc Med. 2017 Apr;27(3):194-202. doi: 10.1016/j.tcm.2017.01.009. Epub 2017 Jan 28. Review.

PMID:
28291655
20.

Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).

Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DA.

Circulation. 2017 May 16;135(20):1911-1921. doi: 10.1161/CIRCULATIONAHA.116.024632. Epub 2017 Feb 28.

Supplemental Content

Loading ...
Support Center